Markets

Alexion (ALXN) Misses on Q2 Earnings, Revises Outlook - Tale of the Tape

Alexion Pharmaceuticals ( ALXN ) focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is sole marketed product of this Cheshire, CT based company.

In this scenario, investor focus remains on Soliris performance and pipeline progress. Alexion is expecting seven product approvals through 2018 including Strensiq, Kanuma and Soliris' label expansion into indications such as antibody-mediated rejection, neuromyelitis optica and the prevention of delayed graft function in renal transplant patients.

Alexion has a mixed earnings track record with the company delivering positive earnings surprises in one of the last four quarters.

Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Alexion's second quarter earnings missed expectations. Our consensus called for EPS of $1.30, and the company reported EPS of $1.12 (these figures include stock-based compensation expense).

Revenue: Revenues were slightly above expectations. Alexion posted revenues of $636.2 million, compared to our consensus estimate of $629 million.

Key Stats: Soliris continues to drive revenues at Alexion. The company revised it's 2015 outlook to include the impact of acquisition of Synageva BioPharma Corp. The company expects adjusted earnings per share in the range of $4.70 to $4.80 per share in 2015 as compared to previous guidance of $5.60 to $5.80 per share.

The company revised its revenue guidance upwards. The company expects revenues in the range of $2.6-$2.62 billion (previous guidance: $2.55-$2.6 billion). Foreign exchange translations are expected to negatively impact revenues by 6%.

Check back later for our full write up on this Alexion earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALXN

Other Topics

Earnings Investing Stocks